IASO: Safety and Gut Microbiota Analysis of an Oral Microbiotherapy in Patients With Amyotrophic Lateral Sclerosis

Sponsor

MaaT Pharma (Industry)

Overall Status

Not yet recruiting

CT.gov ID

NCT05889572

Collaborator

(none)

Enrollment

Locations

Arm

Anticipated Duration (Months)

7.5

Patients Per Site

0.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this pilot study is to assess the safety and tolerability of multiple doses of MaaT033 in ALS patients and to analyze the gut microbiota composition and evolution before considering a larger randomized controlled efficacy study.

Condition or Disease	Intervention/Treatment	Phase
Amyotrophic Lateral Sclerosis	Drug: MaaT033	Phase 1

Detailed Description

This is a prospective, single arm, open-label study.

The target population includes subjects with a recent disease onset defined as the time from first motor deficit at screening of at least 6 months and up to 24 months and removing very rapid/slow progressors based on the ALS Functional Rating Scale - Revised (ALSFRS-R) progression slope.

After a screening period (clinical examination, blood sampling), subject will come for a baseline visit (clinical examination, blood and feces sampling) and to initiate a bowel preparation phase. Five days later, subject will come back to the study site (clinical examination, blood sampling) to initiate a first Maat033 treatment period of 28-day. Ten days after MaaT033 treatment initiation a remote visit is included (feces sampling) to check the subject safety/tolerability. After the first Maat033 treatment period, subject will come to the study site (clinical examination, blood and feces sampling) to initiate the second MaaT033 treatment period of 28-day. At the end of the second Maat033 treatment period subjects will come to the study site (clinical examination, blood and feces sampling) and start a 28-day follow-up period without treatment.

Study completion is defined when all subjects enrolled completed the study follow-up period (clinical examination, blood and feces sampling) or earlier if a subject discontinued the study.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

15 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Safety, Tolerability and Gut microbIota AnalysiS of an Oral Microbiotherapy in Amyotrophic Lateral Sclerosis; an Open-label Phase 1b Pilot Trial

Anticipated Study Start Date :

Jun 1, 2023

Anticipated Primary Completion Date :

Mar 1, 2024

Anticipated Study Completion Date :

Jun 1, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: MaaT033 Route of administration: oral (capsule) Between D-5 to D-1: Bowel preparation with Macrogol and Rifamixin Between D1 to D28: MaaT033 treatment period 1 Between D28 to D56: MaaT033 treatment period 2	Drug: MaaT033 MaaT033 is a Microbiome Ecosystem Therapy (MET), composed of allogeneic, full-ecosystem pooled biotherapeutic gut microbiota.

Arm

Intervention/Treatment

Experimental: MaaT033

Route of administration: oral (capsule) Between D-5 to D-1: Bowel preparation with Macrogol and Rifamixin Between D1 to D28: MaaT033 treatment period 1 Between D28 to D56: MaaT033 treatment period 2

Drug: MaaT033

MaaT033 is a Microbiome Ecosystem Therapy (MET), composed of allogeneic, full-ecosystem pooled biotherapeutic gut microbiota.

Outcome Measures

Primary Outcome Measures

Safety and tolerability: Incidence of Treatment Emergent Adverse Events (TEAE) grade >3, according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 [Day 84]
To assess the safety and tolerability of MaaT033 treatment

Secondary Outcome Measures

Changes in gut microbiota profile [From Day -5 to Day 84 (at Day -5, Day 10, Day 28, Day 56 and Day 84)]
Analysis of fecal samples to assess gut microbiota alpha- and beta-diversity indices
Changes in levels of biomarkers in blood [From Day -5 to Day 84]
Changes from baseline (Day -5) of neutrophil/ lymphocyte ratio, Interleukins (IL): IL-2, IL-6 and IL-8, Interferon gamma (IFNg), Tumor Necrosis Factor alpha (TNFa), Monocyte Chemoattractant Protein-1 (MCP-1), Transforming Growth Factor-beta (TGFb), the soluble subtype of CD14 (sCD14), C-reactive protein (CRP), erythrocyte sedimentation rate, plasma soluble Lipopolysaccharide Binding Protein (LBP), creatinin and serum Short-Chain Fatty Acids (SCFA) at Day 28, Day 56 and Day 84. Changes from baseline (Day -5) of serum Neurofilament light (NfL) at Day 56 and Day 84.
Changes in levels of fecal calprotectin [From Day -5 to Day 84]
Changes from baseline (Day -5) of fecal calprotectin at Day 10, Day 28, Day 56 and Day 84

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 80 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Male or female subjects aged between18 and 80 years
ALS meeting the revised El Escorial criteria for possible, probable, laboratory-supported probable, or definite ALS (familial or sporadic)
Time since first motor deficit at screening: at least 6 months, up to 24 months
Slope of progression of ALS Functional Rating Scale - revised (ALSFRS-R) from date of symptom onset to date of screening test (ΔFS/number of months) between [0.4 and 1.1]
Able to swallow study treatments (including capsules without opening or chewing them) as per the investigator's assessment
SVC (Slow Vital Capacity) equal to or greater than 70% of the predicted normal value for sex, height, and age at the screening visit
If taking riluzole, subject must be on a stable dose for ≥30 days
Signature of written informed consent by subject

Exclusion Criteria:

Subjects with a non-invasive ventilation, a tracheotomy and /or a gastrostomy
Known autoimmune diseases, inflammatory disorders (SLE, Rheumatoid arthritis, connective tissue disorder) or chronic infections (HIV, hepatitis B, or C infection, Tuberculosis)
Known hypersensitivity to rifaximin or macrogol or any of its components
Known allergy or intolerance to trehalose, maltodextrin or Polyethylene Glycol (PEG)
Documented hepatic impairment (Alanine Transaminase/ Aspartate Transaminase > 5N)
Subject with white blood cells < 4000/ mm3; Polynuclear neutrophils < 1.5 G/ L
Active infection requiring systemic antimicrobial therapy within 2-week prior to screening visit
Active infection requiring systemic antimicrobial therapy between screening and baseline
Medical condition requiring proton pump inhibitors (PPIs)
Gastrointestinal obstruction or perforation
Any gastro-intestinal bleeding in the past 3 months
Gastric emptying disorders (gastroparesis)
Toxic megacolon
Severe forms of inflammation of the intestinal tract, including Crohn's disease and ulcerative colitis
Severe vital organ dysfunctions unrelated to ALS and not compatible with experimental treatment, as per the investigator's assessment
Subjects with negative IgG serology for Epstein Barr virus (EBV)
Women of childbearing potential1 without effective contraceptive protection
Nursing or pregnant women
Any condition that, in the opinion of the investigator, may interfere with full participation in the study, including administration of study drug (and its preparation procedure) and attendance at required study visits; represent a significant risk to the subject; or interfere with the interpretation of study data
Enrollment in another trial or expanded access program that may interfere with this study
Guardianship/legal protection/curatorship of subjects
Vulnerable subjects such as: persons deprived of liberty, persons in intensive care units unable to provide informed consent prior to the procedure